BUY HDFC Bank



Deposit/NIM management to take precedence over credit growth ¹⁰

BFSI - Banks > Result Update > April 22, 2024

After the Q3 miss, HDFCB largely ticked all the boxes in Q4 – delivering betterthan-expected deposit growth (over Rs1.7trn QoQ), positively surprising on the margin front (over 3bps QoQ) to 3.63% despite the sharp fall in LDR to 104% and accelerated branch expansion. HDFCB utilized HDFC Credila's stake sale gains of Rs73bn and tax reversal due to favorable court order to shore-up contingent provision buffer (over Rs109bn QoQ) to 1.1% of loans. However, higher staff cost due to ex-gratia provision led to a 3% PAT miss at Rs165bn. Going forward, as per management, ramping up retail deposits and margin management amid potential pressure from lower incremental LDR/inorganic PSL build-up (from Oct-25) to meet sub-targets will take precedence over credit growth. Factoring in slower growth, we have trimmed our earnings estimates for FY25-26E by ~7%. However, we retain BUY with a revised TP of Rs2,000 (earlier Rs2,100), valuing the standalone bank at 2.5x Mar-26E (from 2.7x Dec-25E), partly offset by better subs. valuation (Rs250/sh vs. earlier Rs190/sh).

HDFC Bank: Financia	HDFC Bank: Financial Snapshot (Consolidated)					
Y/E March (Rs mn)	FY22	FY23	FY24	FY25E	FY26E	
Net profit	3,69,614	4,41,087	6,08,123	7,01,782	8,26,630	
Loan growth (%)	20.8	16.9	55.2	11.5	13.0	
NII growth (%)	11.0	20.6	25.0	15.4	15.5	
NIM (%)	3.9	4.1	3.4	3.5	3.6	
PPOP growth (%)	11.7	9.9	34.1	9.3	19.5	
Adj. EPS (Rs)	66.7	79.1	80.0	92.4	108.8	
Adj. EPS growth (%)	18.1	18.6	1.3	15.4	17.8	
Adj. BV (INR)	428.3	497.8	551.5	621.4	704.4	
Adj. BVPS growth (%)	17.5	16.2	10.8	12.7	13.4	
RoA (%)	1.9	1.9	1.8	1.8	1.9	
RoE (%)	16.7	17.0	14.2	15.0	15.7	
P/E (x)	20.5	17.3	16.0	13.9	11.8	
P/ABV (x)	3.2	2.7	2.3	2.1	1.8	

Source: Company, Emkay Research

Retail deposit mobilization, margin management to take precedence over credit growth

HDFCB reported subdued credit growth at 12.5%YoY/1.6% QoQ on a merged basis as the bank continues to run down eHDFCL's corporate book. However, the bank accelerated deposit growth QoQ – Rs1.66trn, including retail deposits at ~Rs1.3trn and the balance being bulk deposits, which in turn led to a sharp reduction in LDR by 600bps QoQ to 104%, thereby easing regulatory concerns. The bank also reported an improvement in LCR to 115%. Despite the sharp fall in LDR, the bank managed to report a slight uptick in NIMs (+3bps QoQ) to 3.63%, much to our and street's surprise. Going forward, management would avoid giving any tangible guidance. However, management reemphasized its stance on retail deposit mobilization and managing margins via a better portfolio mix, replacing eHDFCL's high-cost borrowings and need be a rate hike, amid rising pressure from lower incremental LDR and inorganic PSL build-up to meet sub-targets as the RBI leeway ends in Sep-25.

One-off gains consumed to build a strong contingent provision buffer and, thus, balance-sheet resiliency

HDFCB's headline asset quality continues to improve with the GNPA ratio largely stable at 1.2%, but the bank has shored-up contingent provision buffers (over Rs109bn QoQ) to 1.1% of loans utilizing one-off gains from HDFC Credila's stake sale gains and lower tax incidence due to a favorable court case. This should improve HDFCB's balance-sheet resiliency and tier-II capital ratio, while management indicates that it has no plans to utilize these provisions except for unexpected events. In addition to contingent/floating provision buffer, the bank maintains a healthy specific PCR at 74% and, thus, should help the bank maintain incremental LLP at 0.5-0.6%, amid rising margin pressure.

Retain BUY with a lower TP of Rs2000/share

We have cut our earnings estimates for FY25-26E by ~7%, factoring in slower credit growth and, thus, slightly lower RoA/RoE at 1.8-1.9%/15-16% over FY25-26E. However, we retain BUY with a downward revised TP of Rs2,000 (earlier Rs2,100), valuing the standalone bank at 2.5x its Mar-26E (from 2.7x Dec-25E), partly offset by better subsidiary valuation (Rs250/sh vs. earlier Rs190/sh), including mainly NBFC subsidiary – HDB Financial Services (to come for the IPO in FY25) and HDFC AMC.

TARGET PRICE (Rs): 2,000

	,
Target Price – 12M Change in TP (%) Current Reco. Previous Reco. Upside/(Downside) (%) CMP (19-Apr-24) (Rs)	Mar-25 (4.8) BUY BUY 33.8 1,531.3
Stock Data	Ticker
52-week High (Rs)	1,758
52-week Low (Rs)	1,363
Shares outstanding (mn)	7,596.9
Market-cap (Rs bn)	11,355
Market-cap (USD mn)	1,35,920
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	27
ADTV-3M (Rs mn)	39,696.3
ADTV-3M (USD mn)	475.2
Free float (%)	99.0
Nifty-50	21,996
INR/USD	83.5
Shareholding, Mar-24	
Promoters (%)	-
FPIs/MFs (%)	41.4/29.1

Price Performance					
(%)	1M	ЗМ	12M		
Absolute	3.4	0.6	(9.9)		
Rel. to Nifty	3.5	(1.4)	(27.5)		



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275

Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281


This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/15/2024 01:33 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

3.4

4QFY24

Story in Charts

Exhibit 1: Credit growth slows down; however, deposits growth remains robust



Source: Company, Emkay Research

Exhibit 3: NPA ratio also moderated after a jump in Q2 due to the recognition of stress in eHDFCL's portfolio




Exhibit 4: The bank continued to register a healthy RoA in Q4

Exhibit 2: The bank reported a slight improvement in NIM QoQ

4.3

3QFY23

4.3

2QFY23

4.2

1QFY23

Source: Company, Emkay Research

not comparable with the historical trend

■ NIMs (%)

4.3

4QFY23

Note: Figures from Q2FY24 represent NIM on a merged basis and are, thus,

4.0


1QFY24

34

2QFY24

34

3QFY24



Source: Company, Emkay Research

Source: Emkay Research



5.0 4.5

4.0

3.5

3.0 2.5 2.0


1.5

1.0 0.5

0.0

4.2

4QFY22



Source: Bloomberg, Emkay Research

Exhibit 6: Actuals vs. Estimates (Q4FY24)

(Rs mn)	Actuals	Estin	nates	Variation		Comments
		Emkay	Consensus	Emkay	Consensus	
Net income	4,72,431	4,62,994	4,63,592	2%	2%	High other income led to a beat
PPOP	2,92,742	2,97,837	2,97,101	-2%	-1%	Higher staff cost due to ex gratia provision led to a miss
PAT	1,65,119	1,70,586	1,70,493	-3%	-3%	PPOP miss coupled with higher provisions led to PAT miss

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/15/2024 01:33 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: Key assumptions

	FY23A	FY24E	FY25E	FY26E
Loan Growth (%)	16.9	55.2	11.5	13.0
Deposit Growth (%)	20.8	26.4	22.4	19.9
NIM (%)	4.1	3.4	3.5	3.6
GNPA (%)	1.1	1.2	1.2	1.2
Credit Cost (%)	0.8	0.6	0.5	0.5

Source: Emkay Research

Exhibit 8: Key ratios and trend

(Rs bn)	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24
Loans*	13,688	13,951	14,799	15,068	16,006	16,157	23,312	24,461	24,849
YoY growth (%)	13,688	13,951	14,799	15,068	16,006	16,157	23,312	24,461	24,849
QoQ growth (%)	20.8	21.6	23.4	19.5	16.9	15.8	57.5	62.3	55.2
Composition (%)	8.6	1.9	6.1	1.8	6.2	0.9	44.3	4.9	1.6
- Corporate									
- Retail	52.1	64.1	65.2	63.1	63.9	63.6	48.5	48.5	47.7
- Overseas	44.8	32.4	31.7	34.1	33.5	33.8	51.5	49.8	50.8
QoQ growth (%)	3.1	3.5	3.1	2.8	2.6	2.6	0.0	1.7	1.5
Liability Profile and Margins									
Deposits*	15,592	16,048	16,734	17,332	18,834	19,131	21,729	22,140	23,798
YoY growth (%)	16.8	19.2	19.0	19.9	20.8	19.2	29.8	27.7	26.4
QoQ growth (%)	7.8	2.9	4.3	3.6	8.7	1.6	13.6	1.9	7.5
CA	2393	2206	2300	2277	2735	2524	2477	2558	3100
SA	5117	5141	5297	5352	5625	5606	5700	5799	5987
CASA (%)	48.2	45.8	45.4	44.0	44.4	42.5	37.6	37.7	38.2
CA (%)	15.3	13.7	13.7	13.1	14.5	13.2	11.4	11.6	13.0
SA (%)	32.8	32.0	31.7	30.9	29.9	29.3	26.2	26.2	25.2
NIM (%)	4.2	4.2	4.3	4.3	4.3	4.3	3.6	3.6	3.6
Branches (nos)	6,342	6,378	6,499	7,183	7,821	7,860	7,945	8,091	8,738
Asset Quality and Capital Adequacy (%)									
GNPA	1.17	0.91	0.88	0.89	0.81	0.85	1.34	1.26	1.24
NNPA	0.32	0.25	0.23	0.24	0.20	0.21	0.35	0.31	0.33
PCR	72.6	72.7	73.5	73.0	75.6	75.1	74.2	75.0	73.4
CAR	18.9	18.1	18.0	19.4	19.3	18.9	19.5	18.4	18.8
Tier I	17.9	17.1	17.1	17.2	17.1	16.9	17.8	16.8	16.8
ROE Decomposition (%)									
NII	3.8	3.7	3.6	3.8	3.7	3.3	3.3	3.3	3.3
Other Income (Ex Treasury)	1.5	1.5	1.3	1.4	1.4	1.2	1.2	1.1	1.2
Opex	2.0	2.0	1.9	2.1	2.1	2.0	1.8	1.8	2.0
РРОР	3.3	2.9	3.0	3.1	2.9	2.6	2.7	2.7	3.3
Provisioning Cost	0.7	0.6	0.6	0.5	0.4	0.4	0.3	0.5	1.5
PBT	2.6	2.3	2.4	2.7	2.5	2.2	2.4	2.2	1.8
ROA	2.0	1.8	1.8	2.0	1.9	1.7	1.9	1.9	1.9
Leverage (x)	8.3	8.3	9.2	9.1	9.1	9.7	8.2	8.2	8.1
ROE	16.8	14.7	16.7	18.3	17.2	16.3	15.8	15.5	15.0

Source: Company, Emkay Research; *Represents merged numbers of HDFCB and eHDFCL from Q2FY24

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 05/15/2024 01:33 PM Emkay Research is also available on www.emkayglobal.com and Bioomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

HDFC Bank: Consolidated Financials and Valuations

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Interest Income	12,77,531	16,15,856	25,83,406	29,72,687	33,03,073
Interest Expense	5,57,435	7,47,433	14,98,081	17,20,455	18,56,131
Net interest income	7,20,096	8,68,422	10,85,325	12,52,231	14,46,942
NII growth (%)	11.0	20.6	25.0	15.4	15.5
Other income	2,95,099	3,12,148	4,92,410	5,04,361	6,16,554
Total Income	10,15,195	11,80,571	15,77,735	17,56,592	20,63,495
Operating expenses	3,74,422	4,76,521	6,33,860	7,25,083	8,30,633
PPOP	6,40,773	7,04,050	9,43,874	10,31,509	12,32,862
PPOP growth (%)	11.7	9.9	34.1	9.3	19.5
Core PPOP	6,17,947	7,15,361	8,37,344	9,97,979	11,89,273
Provisions & contingencies	1,50,618	1,19,197	2,34,921	1,14,146	1,36,536
PBT	4,90,155	5,84,853	7,08,953	9,17,363	10,96,326
Extraordinary items	0	0	0	0	(
Tax expense	1,20,541	1,43,766	1,00,830	2,15,580	2,69,696
Minority interest	0	0	0	0	(
Income from JV/Associates	0	0	0	0	(
Reported PAT	3,69,614	4,41,087	6,08,123	7,01,782	8,26,630
PAT growth (%)	18.8	19.3	37.9	15.4	17.8
Adjusted PAT	3,69,614	4,41,087	6,08,123	7,01,782	8,26,630
Diluted EPS (Rs)	66.3	78.7	91.7	91.9	108.2
Diluted EPS growth (%)	17.8	18.6	16.5	0.2	17.8
DPS (Rs)	15.5	19.0	19.5	21.0	24.0
Dividend payout (%)	23.3	24.0	24.4	22.7	22.1
Effective tax rate (%)	24.6	24.6	14.2	23.5	24.6
Net interest margins (%)	3.9	4.1	3.4	3.5	3.6
Cost-income ratio (%)	36.9	40.4	40.2	41.3	40.3
Shares outstanding (mn)	5,545.5	5,579.7	7,596.9	7,596.9	7,596.9

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Share capital	5,546	5,580	7,597	7,597	7,597
Reserves & surplus	23,95,384	27,96,410	43,94,861	49,37,109	55,81,413
Net worth	24,00,929	28,01,990	44,02,458	49,44,706	55,89,010
Deposits	1,55,92,174	1,88,33,946	2,37,97,863	2,91,32,846	3,49,30,01
Borrowings	18,48,172	23,17,656	66,21,531	56,77,801	46,08,24
Interest bearing liab.	1,74,40,346	2,11,51,602	3,04,19,394	3,48,10,647	3,95,38,252
Other liabilities & prov.	8,44,075	7,07,222	13,54,379	8,38,699	9,59,531
Total liabilities & equity	2,06,85,351	2,46,60,815	3,61,76,231	4,05,94,051	4,60,86,793
Net advances	1,36,88,209	1,60,05,859	2,48,48,615	2,77,16,970	3,13,32,541
Investments	45,55,357	51,70,014	70,24,150	79,83,230	89,91,132
Cash, other balances	15,23,269	19,37,651	21,91,474	24,36,745	29,65,369
Interest earning assets	1,97,66,835	2,31,13,524	3,40,64,239	3,81,36,946	4,32,89,042
Fixed assets	60,837	80,165	1,13,990	1,24,876	1,33,916
Other assets	8,57,678	14,67,125	19,98,002	23,32,230	26,63,835
Total assets	2,06,85,351	2,46,60,815	3,61,76,231	4,05,94,051	4,60,86,793
BVPS (Rs)	434.2	503.7	579.5	650.9	735.7
Adj. BVPS (INR)	428.3	497.8	551.5	621.4	704.4
Gross advances	1,38,05,542	1,61,42,365	2,50,79,431	2,79,63,565	3,15,98,829
Credit to deposit (%)	87.8	85.0	104.4	95.1	89.7
CASA ratio (%)	48.2	44.4	38.2	35.9	36.9
Cost of deposits (%)	3.4	3.6	5.0	4.9	4.7
Loans-to-Assets (%)	66.2	64.9	68.7	68.3	68.0
Net advances growth (%)	20.8	16.9	55.2	11.5	13.0
Deposit growth (%)	16.8	20.8	26.4	22.4	19.9
Book value growth (%)	17.2	16.0	15.0	12.3	13.0

Source: Company, Emkay Research

Source: Company,	Emkay Research
Source. company,	Linkay Research

Asset Quality and Other Metrics					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Asset quality					
Gross NPLs	1,61,409.3	1,80,190.0	3,11,732.9	3,42,492.8	3,80,411.4
Net NPLs	44,076.7	43,684.2	80,917.3	95,898.0	1,14,123.4
GNPA ratio (%)	1.2	1.1	1.2	1.2	1.2
NNPA ratio (%)	0.3	0.3	0.3	0.3	0.4
Provision coverage (%)	72.7	75.8	74.0	72.0	70.0
Gross slippages	2,68,614.3	2,45,363.1	4,04,000.0	3,07,599.2	3,79,185.9
Gross slippage ratio (%)	1.9	1.5	1.6	1.1	1.2
LLP ratio (%)	1.2	0.8	0.6	0.5	0.5
NNPA to networth (%)	1.8	1.5	1.8	1.9	2.0
Capital adequacy					
Total CAR (%)	18.9	19.3	18.8	18.5	18.1
Tier-1 (%)	17.9	17.1	16.8	16.7	16.5
CET-1 (%)	16.7	16.4	17.4	17.4	17.6
RWA-to-Total Assets (%)	65.4	64.3	68.2	69.0	70.0
Miscellaneous					
Total income growth (%)	7.7	22.6	59.5	13.0	12.7
Opex growth (%)	14.4	27.3	33.0	14.4	14.6
Core PPOP growth (%)	15.5	15.8	17.1	19.2	19.2
PPOP margin (%)	40.7	36.5	30.7	29.7	31.5
PAT/PPOP (%)	57.7	62.7	64.4	68.0	67.0
LLP-to-Core PPOP (%)	24.4	16.7	28.1	11.4	11.5
Yield on advances (%)	7.9	8.6	10.2	9.2	9.1
Cost of funds (%)	3.5	3.9	5.8	5.3	5.0

Source: Company, Emkay Research

Valuations and Key Ratios Y/E Mar FY22 FY23 FY24 FY25E FY26E P/E (x) 20.5 17.3 16.0 13.9 11.8 P/B (x) 3.1 2.7 2.2 1.7 2.0 P/ABV (x) 3.2 2.7 2.3 2.1 1.8 P/PPOP (x) 11.9 10.9 10.4 9.5 8.0 Dividend vield (%) 1.6 1.0 1.3 1.5 1.4 DuPont-RoE split (%) NII/avg assets 3.8 3.8 3.2 3.3 3.3 Other income 1.5 1.4 1.4 1.3 1.4 Fee income 1.4 1.4 1.1 1.2 1.3 Opex 2.0 2.1 1.9 1.9 1.9 PPOP 3.4 3.1 3.1 2.7 2.8 Core PPOP 3.2 2.8 2.7 3.2 2.6 Provisions 0.8 0.5 0.7 0.3 0.3 Tax expense 0.6 0.6 0.3 0.6 0.6 1.9 RoA (%) 1.9 1.9 1.8 1.8 8.7 8.0 8.2 8.2 Leverage ratio (x) 8.6 RoE (%) 16.7 17.0 14.2 15.0 15.7 Quarterly data Rs mn, Y/E Mar 04FY23 01FY24 **02FY24 O3FY24** 04FY24 NII 2,89,286 2,73,852 2,90,768 2,86,733 2.84.713 NIM(%) 4.1 4.0 3.6 3.6 3.6 PPOP 2,44,573 2,64,709 2,26,939 2,36,473 2,92,742 PAT 1,64,730 1,81,563 1,59,761 1,63,725 1.65.119 EPS (Rs) 21.59 21.37 28.57 29.28 29.53

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 05/15/2024 01:33 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
17-Jan-24	1,538	2,100	Buy	Anand Dama
30-Nov-23	1,559	2,100	Buy	Anand Dama
17-Oct-23	1,541	2,100	Buy	Anand Dama
19-Sep-23	1,629	2,100	Buy	Anand Dama
11-Sep-23	1,632	2,100	Buy	Anand Dama
17-Jul-23	1,679	2,150	Buy	Anand Dama
25-May-23	1,610	2,050	Buy	Anand Dama
24-Apr-23	1,669	2,050	Buy	Anand Dama
15-Apr-23	1,673	2,050	Buy	Anand Dama
09-Mar-23	1,612	1,925	Buy	Anand Dama
15-Jan-23	1,583	1,925	Buy	Anand Dama
04-Jan-23	1,592	1,800	Buy	Anand Dama
16-Oct-22	1,423	1,800	Buy	Anand Dama
04-Oct-22	1,437	1,800	Buy	Anand Dama
17-Jul-22	1,347	1,800	Buy	Anand Dama
01-Jun-22	1,379	1,800	Buy	Anand Dama
23-May-22	1,289	1,800	Buy	Anand Dama
18-Apr-22	1,364	1,950	Buy	Anand Dama
05-Apr-22	1,572	2,050	Buy	Anand Dama
04-Apr-22	1,619	2,050	Buy	Anand Dama
16-Jan-22	1,510	2,050	Buy	Anand Dama
04-Jan-22	1,494	2,050	Buy	Anand Dama
17-Oct-21	1,649	2,050	Buy	Anand Dama
05-Oct-21	1,559	1,850	Buy	Anand Dama
18-Jul-21	1,488	1,850	Buy	Anand Dama

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. It is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/15/2024 01:33 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of April 22, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- З EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of April 22, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the April 22, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/15/2024 01:33 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation from the subject Company in the past 12 months. EGFSL or its associates may have received compensation from the subject Company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.